Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial
…, LA Fecher, GS Falchook, S Nallapareddy… - The lancet …, 2012 - thelancet.com
Background Inhibition of MEK stops cell proliferation and induces apoptosis; therefore, this
enzyme is a key anticancer target. Trametinib is a selective, orally administered MEK1/MEK2 …
enzyme is a key anticancer target. Trametinib is a selective, orally administered MEK1/MEK2 …
Tucatinib plus trastuzumab for chemotherapy-refractory, HER2-positive, RAS wild-type unresectable or metastatic colorectal cancer (MOUNTAINEER): a multicentre …
…, S Ratnam, D Richards, S Nallapareddy… - The Lancet …, 2023 - thelancet.com
Background HER2 is an actionable target in metastatic colorectal cancer. We assessed the
activity of tucatinib plus trastuzumab in patients with chemotherapy-refractory, HER2-positive, …
activity of tucatinib plus trastuzumab in patients with chemotherapy-refractory, HER2-positive, …
Identification of Predictive Markers of Response to the MEK1/2 Inhibitor Selumetinib (AZD6244) in K-ras–Mutated Colorectal Cancer
JJ Tentler, S Nallapareddy, AC Tan, A Spreafico… - Molecular cancer …, 2010 - AACR
Mutant K-ras activity leads to the activation of the RAS/RAF/MEK/ERK pathway in approximately
44% of colorectal cancer (CRC) tumors. Accordingly, several inhibitors of the MEK …
44% of colorectal cancer (CRC) tumors. Accordingly, several inhibitors of the MEK …
Interleukin-6 polymorphism is associated with more aggressive prostate cancer
…, WEI Lou, J Wang, B Janarthan, S Nallapareddy… - The Journal of …, 2005 - Elsevier
PURPOSE: Interleukin-6 (IL-6) has an important role during prostate cancer progression and
IL-6 levels in the serum of patients with hormone refractory and metastatic prostate cancer …
IL-6 levels in the serum of patients with hormone refractory and metastatic prostate cancer …
A phase I dose-escalation, safety and pharmacokinetic study of the 2-methoxyestradiol analog ENMD-1198 administered orally to patients with advanced cancer
Q Zhou, D Gustafson, S Nallapareddy, S Diab… - Investigational new …, 2011 - Springer
Background 2-methoxyestradiol (2ME2) is an estradiol-17β metabolite with antiproliferative
and antiangiogenic activities. ENMD-1198 is an analog of 2ME2 which was developed to …
and antiangiogenic activities. ENMD-1198 is an analog of 2ME2 which was developed to …
Preclinical activity of the rational combination of selumetinib (AZD6244) in combination with vorinostat in KRAS-mutant colorectal cancer models
…, TM Pitts, AM Brown, S Nallapareddy… - Clinical Cancer …, 2012 - AACR
Purpose: Despite the availability of several active combination regimens for advanced
colorectal cancer (CRC), the 5-year survival rate remains poor at less than 10%, supporting the …
colorectal cancer (CRC), the 5-year survival rate remains poor at less than 10%, supporting the …
Chemoradiation is a tolerable therapy for older adults with esophageal cancer
S Nallapareddy, GE Wilding, G Yang, R Iyer… - Anticancer …, 2005 - ar.iiarjournals.org
Introduction: Esophageal adenocarcinoma (EC) is increasing in incidence. Chemoradiation
(CRT) is regarded as an acceptable alternative to surgery for the management of locally …
(CRT) is regarded as an acceptable alternative to surgery for the management of locally …
Biomarker‐driven trial in metastatic pancreas cancer: feasibility in a multicenter study of saracatinib, an oral S rc inhibitor, in previously treated pancreatic cancer
…, NR Foster, J Picus, J Wright, S Nallapareddy… - Cancer …, 2012 - Wiley Online Library
S rc tyrosine kinases are overexpressed in pancreatic cancers, and the oral S rc inhibitor
saracatinib has shown antitumor activity in preclinical models of pancreas cancer. We …
saracatinib has shown antitumor activity in preclinical models of pancreas cancer. We …
Thymidylate synthase (TYMS) enhancer region genotype-directed phase II trial of oral capecitabine for 2nd line treatment of advanced pancreatic cancer
CD Weekes, S Nallapareddy, MA Rudek… - Investigational new …, 2011 - Springer
Purpose The primary aim of this study was to characterize the 6-month overall survival and
toxicity associated with second-line capecitabine treatment of advanced pancreatic cancer …
toxicity associated with second-line capecitabine treatment of advanced pancreatic cancer …
A phase 2/3 randomized study of CTX-009 combination in 2L biliary tract cancer: COMPANION-002.
…, VJM Cline, NM Shumway, MA Tejani, S Nallapareddy… - 2024 - ascopubs.org
TPS587 Background: Biliary tract cancer (BTC) is characterized by generally poor prognoses
with limited treatment options. Systemic chemotherapy usually begins with gemcitabine, …
with limited treatment options. Systemic chemotherapy usually begins with gemcitabine, …